Amdocs signs multi-year extension to provide Cellcom TV with content licensing and content processing
ST. LOUIS – November 10, 2020 – Vubiquity, part of the Amdocs (NASDAQ: DOX) Media Division and one of the leading global providers of premium content services and media technology solutions, today announced it has signed a multi-year extension to its current partnership with Cellcom Israel Ltd., to provide licensing and processing for its leading premium content service Cellcom TV with more than 245,000 subscribers.
Vubiquity holds relationships with over 1,400 content owners, bringing the latest-release content from major studios, plus leading global independent and library classics to provide the best purchased content to Cellcom TV’s customers, including premium content such as HBO, Disney, Warner and NBCU.
Darcy Antonellis, Head of Amdocs Media, said that: “We are extremely pleased to have seized the opportunity to continue our relationship with Cellcom, supporting its highly differentiated and personalized Cellcom TV service, and providing its customers with a best-in-class experience.”
This latest agreement between Amdocs and Cellcom follows an announcement made earlier this year around a deal to accelerate the digitization of Cellcom’s systems, in order to offer its customers an advanced and intuitive digital experience across its lines-of-business.
- Learn more about Amdocs Media’s Vubiquity portfolio
- Keep up with Amdocs news by visiting the company’s website
- Subscribe to Amdocs’ RSS Feed and follow us on Twitter, Facebook, LinkedIn and YouTube
Amdocs’ purpose is to enrich lives and progress society, using creativity and technology to build a better connected world. Amdocs and its 25,000 employees partner with the leading players in the communications and media industry, enabling next-generation experiences in 85 countries. Our cloud-native, open and dynamic portfolio of digital solutions, platforms and services brings greater choice, faster time to market and flexibility, to better meet the evolving needs of our customers as they drive growth, transform and take their business to the cloud. Listed on the NASDAQ Global Select Market, Amdocs had revenue of $4.1 billion in fiscal 2019. For more information, visit Amdocs at www.amdocs.com.
Amdocs’ Forward-Looking Statement
This press release includes information that constitutes forward-looking statements made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995, including statements about Amdocs’ growth and business results in future quarters. Although we believe the expectations reflected in such forward-looking statements are based upon reasonable assumptions, we can give no assurance that our expectations will be obtained or that any deviations will not be material. Such statements involve risks and uncertainties that may cause future results to differ from those anticipated. These risks include, but are not limited to, the effects of general economic conditions, Amdocs’ ability to grow in the business markets that it serves, Amdocs’ ability to successfully integrate acquired businesses, adverse effects of market competition, rapid technological shifts that may render the Company’s products and services obsolete, potential loss of a major customer, our ability to develop long-term relationships with our customers, and risks associated with operating businesses in the international market. Amdocs may elect to update these forward-looking statements at some point in the future; however, the Company specifically disclaims any obligation to do so. These and other risks are discussed at greater length in Amdocs’ filings with the Securities and Exchange Commission, including in our Annual Report on Form 20-F for the fiscal year ended September 30, 2019 filed on December 16, 2019 and our quarterly Form 6-K furnished for the first quarter of fiscal 2020 on February 18, 2020 the second quarter of fiscal 2020 on May 18, 2020 and the third quarter of fiscal 2020 on August 17, 2020.
Amdocs Public Relations
Tel: +44 (0)7896 931 335
Babel PR for Amdocs
Tel: +44 (0)20 7434 5552